Skip to content
‹ Back to IndustriesSciences

Introducing Marc Coenen as the Fiberguide European Account Manager

Fiberguide recently expanded our footprint to better serve our European customers. Marc Coenen, the first Europe-based Fiberguide employee, will support the company’s European distribution network. Fiberguide is working to expand our worldwide footprint, and this exciting new hire is a big step in that direction. Marc has a Master of Science degree in Information Technology…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Promoted Content · · Promoted Content
Share
Introducing Marc Coenen as the Fiberguide European Account Manager

Key takeaways

01

Fiberguide recently expanded our footprint to better serve our European customers.

02

Marc Coenen, the first Europe-based Fiberguide employee, will support the company’s European distribution network.

03

Fiberguide is working to expand our worldwide footprint, and this exciting new hire is a big step in that direction.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Fiberguide recently expanded our footprint to better serve our European customers. Marc Coenen, the first Europe-based Fiberguide employee, will support the company’s European distribution network. Fiberguide is working to expand our worldwide footprint, and this exciting new hire is a big step in that direction.

Marc has a Master of Science degree in Information Technology from the University of Technology Eindhoven in the Netherlands. Prior to joining Fiberguide, he served as Sales Manager Automotive Europe, Area Sales Manager, and Application Engineer at Therm-O-Disc. While all of this experience is undoubtedly important, it’s his belief that “If people like you, they’ll listen to you, but if they trust you they’ll do business with you” that certainly sets Marc Coenen apart from the crowd. It is also in line with Fiberguide’s core values of innovative design, outstanding customer service and unparalleled quality.

“After 12 years at my former company, I was looking for a new challenge in a different field,” Marc explains. “A job where I could learn again, pioneer, and bring added value to the company. Fiberguide offered me that unique position to set up the European sales locally.”

Marc’s goal is to expand Fiberguide’s footprint on the European Fiber Optics map—he’ll be working to grow the Fiberguide business significantly by discovering new accounts and working with our EU partner AMS Technologies. “As distributors sell products from several suppliers, they need to know they will have the support and backing of their vendors,” Marc says. “In my role, I will support them in order to get the inquiries awarded and ensure they have the tools needed to succeed.”

If determination is the secret to success, Fiberguide is poised to enjoy a whole new era of growth in Europe thanks to our new European Account Manager’s focus and skills. If you’d like to connect with Marc to learn more about Fiberguide’s operations in Europe, give him a call at +316 1818 5008 or reach out to him at mcoenen@fiberguide.com.

Read more at fiberguide.com

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

PC
Promoted Content
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Antibody developability checks are moving into discovery instead of waiting for development

Antibody developability checks are moving into discovery instead of waiting for development

Maria Gonzalez-Pajuelo of FairJourney Bio says the order in antibody discovery is changing: developability has become a much more important consideration during discovery, rather than an issue left until later-stage development. The goal, she says, is that what comes out of discovery is something CMC can take forward easily.

  • 01Discovery-stage developability screens can rank many antibodies tested once or twice and may reduce surprises later in development, while development still focuses on several lots of a single antibody and answers different questions.

Oct 1, 2026

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

ISPE’s 2026 Annual Meeting and Expo in Washington, DC organizes its program around five tracks running from discovery to governance, with international program committee chair Connie Langer of Pfizer Global Supply and executive chair Jose Caraballo of JCO Global Advisory LLC describing how the tracks connect—and why AI is treated as a cross-cutting topic rather than a standalone track. Deloitte’s December 2025 survey of 280 executives frames the mood the program is built for.

  • 01ISPE’s 2026 Annual Meeting has no dedicated AI track; executive chair Jose Caraballo expects AI presentations across all five tracks, from discovery to governance.
  • 02Deloitte’s December 2025 survey of 280 biopharma and medtech C-suite executives found more than 75% confident in their own outlook but only 41% optimistic about the global economy, a mood the story says the ISPE chairs are programming for.
  • 03A staffing firm reports life sciences job openings falling even as digital fluency becomes a required skill, so the upskilling burden lands on the people already employed, which is where the mandatory, university-partnered AI training Connie Langer describes at her company sits.

Sep 30, 2026

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site designs preclinical tumor models to match specific therapies and delivery routes, rather than forcing treatments into standard study designs. It combines custom surgical procedures, cell line-derived xenografts, patient-derived xenografts (including post-treatment models), and biomarker capabilities to generate translational data that can help sponsors decide whether to advance a program.

  • 01Orthotopic brain tumor implantation using tagged models lets researchers track tumor growth in the original organ, aligning the model and delivery route with how therapies are intended to be tested.
  • 02Patient-derived xenografts developed from tumors after prior treatment may better reflect progressed disease, helping teams study therapies aimed at patients whose cancer has advanced after earlier treatment.
  • 03Combining biomarker analysis of preclinical model samples with clinical sample testing at one site could make it easier to connect what is measured in animals with what is later measured in patients.

Sep 30, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

PC
Promoted Content

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512